First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis

Inclusion Criteria: 1. The subject is at least 18 years of age. 2. Clinical evidence of ischemic heart disease and/or a positive territorial functional study. 3. Documented stable angina pectoris (Canadian Cardiovascular Society (CCS) Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia 4. The patient has a planned intervention of a single de-novo lesion in one or two separate major epicardial territories (LAD, LCX or RCA). 5. Diameter Stenosis≥50 and\<100%. 6. The visually estimated target lesion must be able to be covered by a single BuMA Supreme stent or a single Resolute Integrity stent (for available sizes refer to tables 1 and 2, page 20 and 21). 7. The target lesion reference diameter must be visually estimated to be ≥2.5 mm and ≤4.5 mm in diameter. 8. Written informed consent. 9. The patient agrees to the follow-up visits including a 9 month angiographic follow-up. 10. Patient must have completed the follow-up phase of any previous study. Exclusion Criteria: 1. Female of child bearing potential (age \<50 years and last menstruation within the last 12 months). Subjects with age \<50 who underwent tubal ligation, ovariectomy or hysterectomy can be included. 2. Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure 3. Patient suffered from stroke/TIA during the last 6 months. 4. LVEF \<30% 5. Platelet count \<100,000 cells/mm3 or \>400,000 cells/mm3, a WBC of \<3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis) 6. Known renal insufficiency (e.g. serum creatinine \>2.5mg/dL, or creatinine clearance ≤30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment). 7. Patient undergoing planned surgery within 6 months with the necessity to stop DAPT. 8. Patient requiring oral anticoagulation (Coumadin, Novel Oral Anticoagulant (NOAC)) 9. History of bleeding diathesis or coagulopathy 10. The patient is a recipient of a heart transplant 11. Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study, sirolimus, zotarolimus, or cobalt-chromium. 12. Other medical illness (e.g. cancer, stroke with neurological deficiency) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy 13. The patient is simultaneously participating in another investigational device or drug study